Following allogeneic blood and marrow transplantation (BMT), the high inverse correlation between graft-versus-host disease (GVHD) and leukemic relapse necessitates that calculated measures be taken to reduce GVHD pathology while retaining a graft-versus-leukemia (GVL) effect. In this regard, we have recently found that in the MHC-matched, minor histocompatibility antigen (miHA) disparate B10.BR->CBA murine model, freshly isolated donor CD4+CD25+ T cells were effective at suppressing early-ongoing CD8+ T cell-mediated GVHD when injected as late as day 10 post-BMT. Of importance, this early regulation of developing GVHD still permitted a potent GVL effect against a host-type myeloid leukemia (MM.CBA6) challenge. The overall goal of the project outlined here is to optimize the conditions for mediating GVHD regulation while maximizing the GVL effect, and to determine the precise cellular mechanisms involved in the elimination of the leukemia cells in vivo and the requirements for regulatory cell activity in order to stop the developing GVHD response. Our working hypothesis is that donor anti-host miHA cytotoxic T lymphocytes (CTL) are generated early after transplantation and readily encounter leukemia cells before they are able to mediate extensive target cell injury of GVHD. The addition of regulatory cells at day 10 post-BMT would then suppress both the GVHD and GVL responses, but the window for GVL interaction was large enough for prior elimination of the leukemic challenge. To test this hypothesis, we will focus on the following specific aims: 1) To determine the optimum conditions and mechanism for regulatory cell control over developing GVHD responses with the longest window of interactive opportunity;2) To determine the mechanism of the GVL activity concomitant with CD4+CD25+ T cell regulation of developing GVHD responses in the B10.BR ->CBA and B6 ->BALB.B models;and 3) To determine the effect of anti-CTLA-4 mAb and GVAX treatments on GVL activity in the context of CD4+CD25+ T cell regulation of developing GVHD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI029530-18
Application #
7800409
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
18
Fiscal Year
2009
Total Cost
$472,051
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Kim, Haesook T; Zhang, Mei-Jie; Woolfrey, Ann E et al. (2016) Donor and recipient sex in allogeneic stem cell transplantation: what really matters. Haematologica 101:1260-1266
Armand, Philippe; Kim, Haesook T; Sainvil, Marie-Michele et al. (2016) The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol 173:96-104
Armand, Philippe; Kim, Haesook T; Logan, Brent R et al. (2014) Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 123:3664-71
Armand, Philippe; Kim, Haesook T; Virtanen, Johanna M et al. (2014) Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant 20:1248-51
Kim, Haesook T; Armand, Philippe (2013) Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom. Biol Blood Marrow Transplant 19:860-6
Matsuoka, Ken-ichi; Koreth, John; Kim, Haesook T et al. (2013) Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 5:179ra43
Armand, Philippe; Gibson, Christopher J; Cutler, Corey et al. (2012) A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 120:905-13
Armand, Philippe; Kim, Haesook T; Zhang, Mei-Jie et al. (2012) Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant 18:280-8
Zilberberg, Jenny; Friedman, Thea M; Dranoff, Glenn et al. (2011) Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia-challenged mice. Biol Blood Marrow Transplant 17:330-40
Kawano, Yutaka; Kim, Haesook T; Matsuoka, Ken-Ichi et al. (2011) Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood 118:5021-30

Showing the most recent 10 out of 25 publications